Search research articles
Contact Us
Filters
Showing results (1-10 of 91) with videos related to
Page
of 10
Sort By:
Pathology, Research and Practice
|
March 1, 2018
SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases
Elisa Schmoeckel, Thomas Kirchner, Doris Mayr
Journal of Ovarian Research
|
July 8, 2021
Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus
Juliane Reichenbach, Elisa Schmoeckel, Sven Mahner, et al.
Plos One
|
February 17, 2018
The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
Marlene Heckl, Elisa Schmoeckel, Linda Hertlein, et al.
Der Pathologe
|
April 1, 2022
[Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification]
Doris Mayr, Lars-Christian Horn, Grit Gesine Ruth Hiller, et al.
Der Pathologe
|
April 12, 2022
[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification]
Lars-Christian Horn, Grit Gesine Ruth Hiller, Doris Mayr, et al.
International Journal of Molecular Sciences
|
June 9, 2017
Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients
Heiko Schulz, Elisa Schmoeckel, Christina Kuhn, et al.
International Journal of Molecular Sciences
|
January 25, 2018
Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9
Heiko Schulz, Christina Kuhn, Simone Hofmann, et al.
Der Pathologe
|
April 6, 2021
[Current WHO classification of the female genitals : Many new things, but also some old]
Doris Mayr, Elisa Schmoeckel, Anne Kathrin Höhn, et al.
Breast Care (Basel, Switzerland)
|
January 23, 2023
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy
Moritz Dimpfl, Doris Mayr, Elisa Schmoeckel, et al.
British Journal of Cancer
|
February 22, 2017
Inhibition of Cdk5 induces cell death of tumor-initiating cells
Melanie M Mandl, Siwei Zhang, Melanie Ulrich, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 91) with videos related to
Sort By:
Page
of 10
Pathology, Research and Practice
|
March 1, 2018
SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases
Elisa Schmoeckel, Thomas Kirchner, Doris Mayr
Journal of Ovarian Research
|
July 8, 2021
Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus
Juliane Reichenbach, Elisa Schmoeckel, Sven Mahner, et al.
Plos One
|
February 17, 2018
The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
Marlene Heckl, Elisa Schmoeckel, Linda Hertlein, et al.
Der Pathologe
|
April 1, 2022
[Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification]
Doris Mayr, Lars-Christian Horn, Grit Gesine Ruth Hiller, et al.
Der Pathologe
|
April 12, 2022
[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification]
Lars-Christian Horn, Grit Gesine Ruth Hiller, Doris Mayr, et al.
International Journal of Molecular Sciences
|
June 9, 2017
Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients
Heiko Schulz, Elisa Schmoeckel, Christina Kuhn, et al.
International Journal of Molecular Sciences
|
January 25, 2018
Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9
Heiko Schulz, Christina Kuhn, Simone Hofmann, et al.
Der Pathologe
|
April 6, 2021
[Current WHO classification of the female genitals : Many new things, but also some old]
Doris Mayr, Elisa Schmoeckel, Anne Kathrin Höhn, et al.
Breast Care (Basel, Switzerland)
|
January 23, 2023
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy
Moritz Dimpfl, Doris Mayr, Elisa Schmoeckel, et al.
British Journal of Cancer
|
February 22, 2017
Inhibition of Cdk5 induces cell death of tumor-initiating cells
Melanie M Mandl, Siwei Zhang, Melanie Ulrich, et al.
Page
of 10